Article | January 11, 2021

Biosimilars: Evolving Challenges And Considerations

By Zoltan Gulyas, Thermo Fisher Scientific

Pharma Lab Worker

It is a common misconception that biosimilar development is a less-complex process compared to novel biologics development. By the time of patent expiry and entry of biosimilars to the market, the innovator product has been used for years, demonstrating the efficacy and safety of the treatment. Biosimilar developers can leverage this experience: the regulatory framework enables an abbreviated clinical program that focuses on pharmacokinetics/pharmacodynamic (PK/PD) and immunogenicity assessments, but places emphasis on demonstrating high similarity to the reference product. The biosimilar candidate must be characterized by a wide variety of state-of-the-art analytical techniques, and all critical quality attributes (CQAs) must be comparable to the reference product.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: